Nanoviricides--Alive and Kicking!

[JustHanginginThere]

I know we spend a lot of time talking about vaccines but there are also exciting developments in topicals. As you all might remember Nanoviricides was pursuing FluCide and HerpeCide earlier this year and it was sounding like FluCide was going to be their first drug.  Then later in the year they reported dramatic effects of HerpeCide and decided to accelerate that program in front of FluCide. This is obviously huge news as it is my opinion (from the results) that the drug most likely blow away any available topical.  In addition, it is my opinion (from the result) it could have potential for equal or better efficiency than taking oral drugs (e.g., Valtrex, Famvir).  The good thing is there is no potential for drug resistance—it simply kills the virus. 

Members of this board have spoken to the CEO (Dr. Seymour) and find him sympathetic and understanding.  This is most likely because he spent years treating patients as an Infectious Disease doctor and understands viruses well.  He is enthusiastic about bringing a product to market that will help all of us.  The current goal is to move to Toxicity testing for HerpeCide as soon as possible and submit an IND for HerpeCide.  Then they can move forward to Phase 1 in Humans. 

Vaccines won’t work for everyone so it is good to know there are other treatments coming.

Below are the excerpts from their Press Release:

“The Company reports that its HerpeCide™ program is advancing well. We anticipate developing topical drugs to control herpesvirus outbreaks for a number of indications under this program. These include oral lesions or "cold sores", usually caused by HSV-1, genital lesions, usually caused by HSV-2, and shingles outbreaks in adults, caused by reactivation of the chickenpox virus (varicella Zoster virus, or HHV-3). In addition, the Company is also developing eye drops for the treatment of herpes keratitis (HK) of the eye, and for epidemic adenoviral conjunctivitis (EKC). The Company believes, assuming the results from our animal studies are indicative of future human clinical success, that these various drug candidates under the HerpeCide program should result in extremely effective drugs.

“The Company believes, based on various professional inputs it has obtained, that the different topical herpesvirus treatments would move towards the clinical stage faster than our Injectable FluCide™ for hospitalized patients. This is based on the limited studies needed for safety/toxicology, as well as for efficacy, for a topical drug against herpesviruses, as opposed to an injectable drug against the highly variable influenza viruses.”

Website: http://www.nanoviricides.com/

[Franticheart]

This is good to see! the more things being developed the better I say. :-) Would this be used to prevent transmission?

Hope it does well in clinical trials -  hoping for the best! 

Edited November 30, 2015 by worried89